SOURCE: OctoPlus N.V.

April 23, 2007 01:45 ET

OctoPlus appoints new Scientific Advisory Board members

LEIDEN, NETHERLANDS -- (MARKET WIRE) -- April 23, 2007 --



OctoPlus N.V. (Euronext: OCTO), the drug delivery and development company, announces today that it has appointed three new members to its Scientific Advisory Board: professor Ab Osterhaus, professor Douwe Breimer and professor Peter van Brummelen. Current chairman professor Daan Crommelin and professor Wim Hennink will continue their work on the board. Three members will step down: professor Jan Feijen, professor Bert Leufkens and dr. Paul Morrison.

Prof.dr. Ab Osterhaus is a leading authority in the area of virology and brings thirty years of experience in animal and human virology to OctoPlus' Scientific Advisory Board. Professor Osterhaus started his career in Utrecht (the Netherlands) where he graduated with distinction at the faculty of veterinary sciences and received his Ph.D. degree with distinction in 1978. He has been instrumental in scientific progress made at the RIVM (the Dutch National Institute for Public Health and the Environment) and Erasmus Medical Center in Rotterdam. He has written over 650 academic articles, created biotech companies and held several editorial positions.

Prof.dr. Douwe Breimer is professor of pharmacology at Leiden University since 1975. He was Rector Magnificus of Leiden University from 2001 to 2007. He is (co)-author of more than 500 scientific papers in the areas of pharmacology, biopharmaceutics, pharmacokinetics and drug metabolism. Professor Breimer received several scientific distinctions including seven honorary doctorates. He is Chairman of the Board of Directors of venture capital firm Life Sciences Partners and was a member of the national Innovation Platform of the Netherlands.

Prof.dr. Peter van Brummelen is an independent drug development consultant and board member of several biotech companies. From 1988 to 2003 he served in executive positions at Yamanouchi Europe, Solvay Pharmaceuticals and Hoffmann La Roche, where he contributed substantially to the successful development of various new drugs in different therapeutic classes. Professor Van Brummelen has an M.D. and Ph.D. from Leiden University. He was also a board certified specialist in internal medicine and held various positions at the universities of Leiden and Basel (Switzerland). He (co-)authored over 200 scientific publications.

"We are pleased to welcome these three new members to our Scientific Advisory Board and look forward to their valuable input to OctoPlus in the future," comments Joost Holthuis, CEO of OctoPlus. "We would like to acknowledge professor Feijen, professor Leufkens and dr. Morrison for their contribution to the success of our company."

For further information, please contact:
Rianne Roukema, Corporate Communications: +31 (71) 524 4044
About OctoPlus

OctoPlus N.V. is a product-oriented biopharmaceutical company committed to the development of improved pharmaceutical products that are based on its proprietary drug delivery technologies and have fewer side effects, improved patient convenience and a better efficacy/safety balance than existing therapies. Rather than seeking to discover novel drug candidates through early stage research activities, OctoPlus focuses on the development of long-acting, controlled release versions of known protein therapeutics and other drugs.

OctoPlus is also a leading provider of advanced drug formulation and clinical scale manufacturing services to the pharmaceutical and biotechnology industry, with a focus on difficult to formulate active pharmaceutical ingredients in injectable formulations. The earnings and expertise that OctoPlus derives from rendering formulation and manufacturing services help to support its own drug development programs.

OctoPlus is listed on Euronext Amsterdam under the symbol OCTO. For more information about OctoPlus, please visit our website www.octoplus.nl.

This document may contain certain forward-looking statements relating to the business, financial performance and results of OctoPlus N.V. and the industry in which it operates. These statements are based on OctoPlus N.V.'s current plans, estimates and projections, as well as its expectations of external conditions and events. In particular the words "expect", "anticipate", "predict", "estimate", "project", "plan", "may", "should", "would", "will", "intend", "believe" and similar expressions are intended to identify forward-looking statements. We caution investors that a number of important factors, and the inherent risks and uncertainties that such statements involve, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements. In the event of any inconsistency between an English version and a Dutch version of this document, the English version will prevail over the Dutch version.





Copyright © Hugin ASA 2007. All rights reserved.

Contact Information